(833) 317-6278
Book a Demo
David Saltzman
Gray shield icon
Is this you?
Claim your profile.

David Saltzman

AS SEEN ON
BenefitsPRO, InsuranceNewsNet, Ropes & Gray LLP

Preston's Summary

David Saltzman is a journalist and writer who focuses on healthcare and business topics. He writes for publications such as BenefitsPRO, Baker Botts, and Ropes & Gray LLP, covering subjects such as direct primary care, health care costs, transparency in the industry, and mergers and acquisitions. David's articles aim to provide insights and analysis on important issues in the healthcare and business sectors.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

United States (National)

Coverage Attributes:

Beta
Expert Commentary: 39 %
Industry Specific: 18 %
Private Sector Announcements: 12 %
Press Release: 9 %
Exclusive: 3 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

Not enough data icon

Not enough data

Pitching Insights

David Saltzman's coverage indicates a focus on in-depth analysis and expert commentary within the healthcare, pharmaceutical, and business sectors. He may be particularly interested in pitches that provide insights into emerging trends or significant developments within these industries.

Given his emphasis on industry-specific content and expert commentary, he would likely respond well to pitches from professionals with deep expertise in healthcare policy, pharmaceuticals, business strategy, or related fields. These experts should be able to offer unique perspectives on industry changes and their implications for businesses and consumers.

As David does not have a specific geographic focus mentioned, it is important to tailor the pitch based on its relevance across various markets rather than focusing solely on one region.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Allison Bell

Allison Bell

Senior Reporter
****l@******m
Publications
BenefitsPRO, A Girls Guide to Cars, Treasury & Risk, PropertyCasualty360.com
Most recent topics
Not enough data
Lynn Varacalli Cavanaugh

Lynn Varacalli Cavanaugh

********gh@******m
Publications
BenefitsPRO
Most recent topics
Not enough data
Alison Kuhlow

Alison Kuhlow

Advocacy and Government Relations
*****n@*************org
Publications
KPCW Radio
Most recent topics
Not enough data
Lily Peterson

Lily Peterson

Editor
*******on@******m
Publications
BenefitsPRO
Most recent topics
Not enough data
Rebekah Mcclelland

Rebekah Mcclelland

Publications
Central Penn Business Journal, Lehigh Valley Business
Most recent topics
Not enough data
Scott Wooldridge

Scott Wooldridge

Publications
BenefitsPRO
Most recent topics
Not enough data

Articles

Ropes & Gray LLP

Ropes & Gray Advises on the Launch of Kailera Therapeutics

By: Amanda Holt, David Saltzman

Ropes & Gray advised Kailera Therapeutics, Inc. and its investors on the establishment of the company, its $400 million Series A financing, and the worldwide (ex-China) licensing by the company of a portfolio of clinical-stage metabolic disease assets from Hengrui Pharmaceuticals, a leading Chinese pharmaceutical company. Atlas Venture, Bain Capital Life Sciences, and RTW Investments led the Series A financing, with participation from Lyra Capital.

Ropes & Gray LLP

Ropes & Gray Advises Apollo Therapeutics on Exclusive Ex-China License for Clinical-Stage FGF21/GLP-1 Dual Receptor Agonist

By: David Saltzman

Ropes & Gray advised Apollo Therapeutics in a licensing agreement with Sunshine Lake Pharma Co., Ltd., a member of China’s HEC Group, pursuant to which Apollo Therapeutics will receive exclusive ex-China rights to develop and commercialize HEC88473, a clinical-stage FGF21/GLP-1 dual receptor agonist developed by Sunshine Lake that has potential in multiple disease areas. The transaction was announced on Nov. 12.

© 2025 Intelligent Relations